the good results keep coming. not sure we will get a huge re-rate until phase 2 gets in patients in a live scenario, but could be a steady climb if further pre clinical keeps pumping out these type of results.
Sort of reminds me of when the lithium co's PLS etc... were dirt cheap against the backdrop of covid, going down to 20 cents, those who bought simply put a 'set and forget', now 20 bags later in a matter of years. reckon AGN has that kind of feel to it, given the MC of $37M.
Ann: Latest Preclinical HIE Study Results, page-13
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
80.0¢ |
Change
0.015(1.91%) |
Mkt cap ! $101.7M | |||
| Open | High | Low | Value | Volume |
| 82.0¢ | 87.0¢ | 79.0¢ | $248.4K | 298.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2228 | 79.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 85.5¢ | 20500 | 2 |
View Market Depth
| Last trade - 15.59pm 06/09/2024 (20 minute delay) ? |
| AGN (ASX) Chart |